Find clinical trials in your area
Search by disease and location to discover available clinical trials matching your criteria.
↓
Matched clinical trials
Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients
Recruiting
Investigated diseases:Investigated drugs:
+9
Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back
Recruiting
Investigated diseases:Investigated drugs:
Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6
Recruiting
Investigated diseases:Investigated drugs:
+2
Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression
Recruiting
Investigated diseases:Investigated drugs:
Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Recruiting
Investigated diseases:Investigated drugs:
Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel
Recruiting
Investigated diseases:Investigated drugs:
Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment
Recruiting
Investigated diseases:Investigated drugs:
+6
Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer
Recruiting
Investigated diseases:Investigated drugs:
Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment
Recruiting
Investigated diseases:Investigated drugs: